These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 9269642

  • 21. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K, Kakuta H.
    Eur J Pharmacol; 2015 Nov 05; 766():129-34. PubMed ID: 26452517
    [Abstract] [Full Text] [Related]

  • 22. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
    Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT.
    Am J Kidney Dis; 2006 Sep 05; 48(3):437-44. PubMed ID: 16931217
    [Abstract] [Full Text] [Related]

  • 23. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
    Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wada M.
    Nephrol Dial Transplant; 2003 Oct 05; 18(10):2014-23. PubMed ID: 13679475
    [Abstract] [Full Text] [Related]

  • 24. Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats.
    Zeng M, Wang X, Wang X, Zhao X.
    Ren Fail; 2012 Oct 05; 34(3):358-63. PubMed ID: 22260362
    [Abstract] [Full Text] [Related]

  • 25. Use of sevelamer hydrochloride as an oxalate binder.
    Lieske JC, Regnier C, Dillon JJ.
    J Urol; 2008 Apr 05; 179(4):1407-10. PubMed ID: 18289565
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB, Smeeding JE, Brook RA.
    Curr Med Res Opin; 2004 Jul 05; 20(7):991-9. PubMed ID: 15265243
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Jul 05; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 30. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G, Cardinal H, Mailhot M, Ste-Marie LG, Roy L.
    Ther Apher Dial; 2010 Apr 05; 14(2):172-7. PubMed ID: 20438539
    [Abstract] [Full Text] [Related]

  • 31. The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients.
    Fournier A, Oprisiu R, Albu AT, Dungaciu M, El Esper N, Mornière P.
    Am J Kidney Dis; 2000 Jun 05; 35(6):1248-50. PubMed ID: 10877727
    [No Abstract] [Full Text] [Related]

  • 32. Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats.
    Yamaguchi T, Baxter JG, Maebashi N, Asano T.
    Ren Fail; 1999 Sep 05; 21(5):453-68. PubMed ID: 10516989
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V, Torres Ramírez A.
    Drugs Aging; 2004 Sep 05; 21(3):153-65. PubMed ID: 14979734
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.
    Am J Kidney Dis; 2009 Oct 05; 54(4):619-37. PubMed ID: 19692157
    [Abstract] [Full Text] [Related]

  • 40. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 05; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.